Skip to main content Skip to main navigation menu Skip to site footer

Dramatic improvement in severe-critical COVID-19 patient after tocilizumab administration: a clinical experience

  • Yesicha Kurniawati ,
  • Kadek Surya Atmaja ,
  • Ketut Suryana ,
  • Wayan Wahyu Semara Putra ,


Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in coronavirus disease 2019 (COVID-19) involve so many inflammatory cytokines, especially Interleukin-6 (IL-6). The usage of tocilizumab as an anti-IL-6 receptor antibody had been approved as COVID-19 medication.

Case Presentation: This article reports a 51-year-old woman diagnosed with severe-critical COVID-19. The patient made significant progress after tocilizumab administration. The patient was hospitalized for 14 days before being discharged.

Conclusion: Tocilizumab administration showed a significant improvement in COVID-19 patients.  However, further investigations are needed to explain this further.


  1. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427. doi:10.1016/j.clim.2020.108427.
  2. World Health Organization. Weekly epidemiological update. 2021. Available from:
  3. Adityo S, Martin R, Ceva W, et al. Coronavirus Disease 2019: Review of Current Literatures. JPDI. 2020;7(1):45-67. doi: 10.7454/jpdi.v7i1.415.
  4. Samudrala PK, Kumar P, Choudhary K, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. EJP. 2020;883:173375. doi:10.1016/j.ejphar.2020.173375.
  5. Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. 2020;12(4):372. doi:10.3390/v12040372.
  6. Ezzikouri S, Nourlil J, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development. Hum Vaccin Immunother. 2020;16(12):2992-3000. doi:10.1080/21645515.2020.1787068.
  7. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. doi:10.1183/13993003.00607-2020.
  8. Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41(12):1100-1115. doi:10.1016/
  9. Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ. 2020;371:m3862. doi:10.1136/bmj.m3862.
  10. Ebrahimi N, Aslani S, Babaie F, et al. Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. Int Immunopharmacol. 2020;89(Pt B):107082. doi:10.1016/j.intimp.2020.107082.
  11. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi:10.1016/j.ijantimicag.2020.105954.
  12. Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38-42. doi:10.1016/j.cytogfr.2020.04.002.
  13. Wang Y, Lu X, Li Y, et al. Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19. Am J Respir Crit Care Med. 2020;201(11):1430-1434. doi:10.1164/rccm.202003-0736LE.
  14. Esmaeilzadeh A, Elahi R. Immunobiology and immunotherapy of COVID-19: A clinically updated overview. J Cell Physiol. 2021;236(4):2519-2543. doi:10.1002/jcp.30076.
  15. Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020;50(5):397-400. doi:10.1016/j.medmal.2020.05.001.

How to Cite

Kurniawati, Y., Atmaja, K. S., Suryana, K., & Putra, W. W. S. (2021). Dramatic improvement in severe-critical COVID-19 patient after tocilizumab administration: a clinical experience. Intisari Sains Medis, 12(1), 338–340.




Search Panel

Yesicha Kurniawati
Google Scholar
ISM Journal

Kadek Surya Atmaja
Google Scholar
ISM Journal

Ketut Suryana
Google Scholar
ISM Journal

Wayan Wahyu Semara Putra
Google Scholar
ISM Journal